72-week post-hoc analysis of SURMOUNT-1 trial reveals that 30% of slow tirzepatide responders lost 15% or more weight.
A post-hoc analysis of the SURMOUNT-1 trial shows that most 'slow responders' to tirzepatide, a weight-loss medication, achieved 5% or greater weight reduction at 72 weeks. Among 1,545 adults, 30% of slow responders lost 15% or more. The findings suggest that tirzepatide treatment may need longer than 12 weeks for full weight-loss response, and further studies are needed to understand weight-loss variability with the medication.
May 10, 2024
3 Articles